Living meta-analysis and evidence synthesis of therapies for COVID-19

click on circles to display study description...

VERU-111, 2022 NCT04842747

sabizabulin (n=134) vs. placebo (n=70)

randomized controlled trial   some concerns about risk of bias

Studied treatment

daily oral doses of sabizabulin 9mg for 21 days

Control treatment

placebo

Patients

COVID-19 mild to moderate

Method

double-blind

27 centers, worldwide

met the prespecified superiority criterion for efficacy at the time of the interim analysis with 150 patients

Remark

planned interim analysis